Pharming Group NV:
Human protein replacement therapies, initially in rare/ultra-rare diseases, plus new small molecule program for APDS. RUCONEST (rhC1INH), the only recombinant enzyme replacement therapy marketed for acute Hereditary Angioedema (HAE) attacks and being developed for large unmet indications. Profitable and cash flow positive – revenue from product sales €134M (2018) and €123M (1st 9 months 2019). Growth (9 mo. YOY) in revenues (+26%), operating profit (+38%) and net profit (+73%). Development pipeline includes RUCONEST in new versions (LCM), new license from Novartis of late stage drug Leniolisib for APDS (ultra-rare immunodeficiency condition), rhC1INH for new larger indications including pre-eclampsia (data exp. Q3 2020) and AKI, recombinant alpha-Glucosidase for Pompe disease.
Anti-inflammatory, Autoimmune, Rare Disease
500MM - 1B
Leiden, 2333 CR
Top 10 Holders of Pharming Group NV
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by